Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.